Brief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
BRIEF-Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities Oct 23 (Reuters) - Tango Therapeutics, Inc. TNGX.O:
TANGO THERAPEUTICS, INC.: APPROVED A STRATEGIC REPRIORITIZATION OF THE COMPANY’S RESEARCH AND DEVELOPMENT ACTIVITIES
TANGO THERAPEUTICS, INC.: INTENDS TO REDUCE ITS OVERALL WORKFORCE BY APPROXIMATELY 14%
TANGO THERAPEUTICS,.: INTENDS TO REDUCE OVERALL WORKFORCE BY 14%, WITH THE MAJORITY OF THE HEADCOUNT REDUCTIONS FROM THE CO'S RESEARCH GROUP
TANGO THERAPEUTICS,.: INTENDS TO STOP CERTAIN PRECLINICAL AND RESEARCH ACTIVITIES TO FOCUS ON TRANSLATIONAL WORK AND ITS PRMT5 PROGRAMS
TANGO THERAPEUTICS: TO FOCUS EFFORTS ON ADVANCEMENT OF PRMT5-TARGETED THERAPIES AND CLINICAL PRODUCT CANDIDATES, VOPIMETOSTAT AND TNG456
Source text: [ID:n0001193125-26-429423]
Further company coverage: TNGX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,